Clinical significance of microembolus detection by transcranial Doppler sonography in cardiovascular clinical conditions

Narcis Hudorović*

University Department of Vascular and Endovascular Surgery, University Hospital "Sestre Milosrdnice", 10000 Zagreb, Vinogradska 29, Croatia

KEYWORDS
Cerebral embolism; Ultrasonography; Pathophysiology; Cardiovascular pathology; Microemboli

Abstract
Transcranial Doppler can detect microembolic signals, which are characterized by unidirectional high intensity increase, short duration, and random occurrence, producing a "whistling" sound. Microembolic signals have been proven to represent solid or gaseous particles within the blood flow. Microemboli have been detected in a number of clinical cardiovascular settings: carotid artery stenosis, aortic arch plaques, atrial fibrillation, myocardial infarction, prosthetic heart valves, patent foramen ovale, valvular stenosis, during invasive procedures (angiography, percutaneous transluminal angioplasty) and surgery (carotid, cardiopulmonary bypass). Despite numerous studies performed so far, clinical significance of microembolic signals is still unclear. This article provides an overview of the development and current state of technical and clinical aspects of microembolus detection.

© 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

Introduction
Embolization is the cause of ischemic stroke in 40–80% of cases.1 Transient ischemic attack (TIA) is a warning sign of stroke; it is often caused by emboli lodged in a distal artery that underwent successful anastomosis or lysis.2 In the last 15 years a substantial number of studies dealing with emboli detection have been performed, while the clinical relevance of so-called microembolic signals (MES, old terminology was high intensity transient signals HITS) is still under debate. MES are proven to represent emboli passing within cerebral circulation.2 Emboli are particles of platelets, fibrinogen, cholesterol, fat, particles of disrupted plaque (trombus) or gas bubbles that travel through circulation. First studies on emboli detection have been performed in the 1960s.3 In 1990 Spencer et al. reported on patients undergoing carotid endarterectomy (CEA) in whom
microembolic signals (MES) could be detected during the preparation phase of the artery, before opening of the artery lumen; detected microembolic signals (MES) were assumed to represent emboli. Ever since, emboli have been detected in a number of cardiovascular conditions: carotid artery stenosis, aortic arch plaques, atrial fibrillation, myocardial infarction, prosthetic heart valves, patent foramen ovale, valvular stenosis, during carotid surgery, open heart surgery, stent implantation, percutaneous transluminal angioplasty, and angiography. Clinical significance of emboli detected in cerebral circulation is still unclear. While the vast majority of microembolic signals (MES) are asymptomatic, there is substantial evidence at disposal that MES are relevant in certain clinical conditions. Consensus regarding emboli detection has been made, since different researchers had different identification criteria for emboli. The most important technical parameters affecting the detectability of microembolic signals are as follows:

1. Relative intensity increase — ratio of the acoustic power backscattered from the embolus to that of the moving blood surrounding the embolus; it is usually measured in decibels.
2. Detection threshold — ranging from 3 to 9 dB has been recommended.
3. Size of the sample volume — most investigators use a value of sample volume length between ≥10 mm.
4. Fast Fourier Transform (FFT) frequency resolution and temporal resolution — the frequency resolution is given by the reciprocal of temporal resolution; the greater the number of points used for the FFT the poorer the temporal resolution; therefore a compromise is necessary. At present 64, 128 or 256 frequency bins are preferred.
5. Fast Fourier Transform (FFT) temporal overlap — FFT overlap of at least 50% is essential; smaller overlaps (e.g., 10%) impose the risk of missing individual microembolic signals.
6. Dynamic range of the instrumentation — a wide dynamic range prevents overloading of the receiver. Dynamic range depends on the manufacturer; devices presently marketed have dynamic ranges on the order of 30–50 dB.
7. Transmitted ultrasound frequency — a frequency of 2 MHz is most frequently used; the sensitivity is lower with higher frequencies.
8. Filter settings — high-pass filters suppress low frequencies originating from arterial wall oscillation; the level of high- and low-pass filters should be kept constant.
9. Recording time — it depends on the study population (see below).

**Characteristics of microembolic signals (MES)**

1. Short lasting (<0.01–0.03 s) intensity increase,
2. unidirectional intensity increase (>3 dB) within the Doppler frequency spectrum,
3. intensity increase focused around one frequency,
4. random occurrence within the cardiac cycle,
5. produce a “whistle”, “chirping” or “clicking” sound when passing through the sample volume.

**Artifacts**

Artifacts also cause intensity increase of Doppler spectrum. Artifacts can be caused by patient moving the head, coughing, chewing or any movement that are causes by artifacts will be present as bidirectional (above and under the zero line). Large, solid emboli or gaseous emboli may cause overload of the receiver which can produce similar signals as artifacts. Therefore it is important that the transcranial Doppler sonography (TCD) machine has a wide dynamic range (at least 50 dB). Artifacts cause intensity increase usually of low frequency, around the zero line and produce sounds like “rumble”.

**Materials and methods**

TCD machine should have a special software for emboli detection with a sufficient dynamic range. Two 2 MHz frequency probes should be connected to a band or aluminum wire which is placed on the patient’s head. The machine should have automatic saving of every change of Doppler spectrum caused by frequency shift, so detailed analysis can be performed later as many times as required. Video taping of the recordings is even better because not all softwares have the possibility to reproduce sound which is an important characteristic of emboli. Fast Fourier transform (FFT) signal processing is widely used in the evaluation of microembolic signals (MES). In FFT based calculations, the time window overlap is of considerable importance; MES falling between two FFT intervals are likely to appear smaller than those in the middle, and if the overlap is very small MES can even
disappear. Modern equipment seldom encounters insufficient overlaps, if older technology is being used, then window overlap should be taken into consideration when assessing MES. New TCD machines, "multigate Doppler", enable better differentiation of emboli from artifacts. Two sample volumes are placed at a distance of at least 5 mm, one from another, which enable recording of Doppler spectrum at two depths of an artery. When the embolus is moving from proximal to distal part of the artery, it passes two gates (sample volumes) and is then recorded twice with a delay in time, showing in the spectrum as two different appearances. Artifacts are recorded simultaneously in both sample volumes and make the same appearance. The main criterion for differentiation of MES and artifacts in multigate Doppler machines is time difference of MES. Emboli analysis other than FFT calculation is being improved with other methods such as Wigner distribution function, narrow band hypothesis, non-linear forecasting, frequency filtering of time domain data, and wavelet transformation. A new transcranial modality, power M-mode Doppler (PMD), has been developed to overcome the difficulties in location and insonation through transcranial ultrasound windows. PMD has 33 sample gates placed with 2-mm spacing for display of Doppler signal power, colored red and blue for directionality, in an M-mode format. The spectrogram from a user-selected depth is displayed simultaneously. PMD facilitates window location and alignment of the ultrasound beam to view blood flow from multiple vessels simultaneously, without sound or spectral clues. Microemboli appear as characteristic sloping high-power tracks in the power M-mode Doppler (PMD) image. Although technological improvement in the area of emboli detection has recently been achieved, it is still impossible to reliably distinguish the composition of emboli. In vivo and in vitro studies have tried to differentiate gaseous from solid emboli. Differentiation between solid and gaseous microemboli is based on the principle that solid emboli reflect more ultrasound at higher frequency, whereas the opposite is the case for gaseous emboli. This principle is used in multifrequency TCD instrumentation where the vessels are insonated simultaneously with 2.5 and 2.0 MHz and can be used for the differentiation between gaseous and solid emboli. Differentiation of solid and gaseous emboli has also been demonstrated by oxygen inhalation. Intensity, duration and frequency are useful to distinguish between the two, however, it is still impossible to differentiate between particles of fat, platelet aggregates or particles of atheroma.

The aluminum wire (or tight rubber band) is placed on the patient’s head, and both middle cerebral arteries (MCA) are insonated through temporal windows. When the Doppler signal is located, it is important to achieve a clear signal from the depth of 45–55 mm; insonation too close to the carotid siphon may result in recordings of false positive signals which are caused by blood turbulence. At 45–55 mm depths the blood stream is mostly laminar and turbulence is not expected. After achieving a clear signal, the probes are fixed; monitoring is performed over at least 1 h (extended monitoring is preferable is cooperative).

**Monitoring time**

Optimal time of monitoring depends on the clinical entity. In patients with implanted artificial heart valves in whom microembolic signals (MES) can be detected in large proportion, monitoring for 30 min will be sufficient. In patients with atrial fibrillation or other cardiac disease, or carotid artery stenosis the frequency of emboli is usually low, 1–2 emboli signals over 60 min. Extended monitoring, for more than 1 h, or repetitive monitoring over a couple of days in succession, is in relation with the percentage of emboli positive patients. Embolic activity is highest in the first couple of hours after stroke; however, emboli may be detectable days and weeks after cerebrovascular incidents, which means that those patients are at a higher risk of stroke. It must be highlighted that patients who have no recorded emboli signals (even on repetitive monitoring) cannot be declared as "emboli negative". However, patients who have detectable emboli, especially in larger numbers, should be considered as high risk patients for stroke. Emboli detection may help in the localization of embolic source: emboli detected in both middle cerebral arteries (MCAs) are usually from cardiac source, and emboli detected ipsilaterally to a carotid artery stenosis are probably dislodged from intraluminal thrombus or plaque disruption. Although emboli monitoring is considered as a safe and noninvasive method, a small number of studies have focused on this issue. In vivo studies have shown that bilateral monitoring of middle cerebral arteries (MCA) with 530 mW/cm² over 8 h caused no abnormal immediate or late changes of the tissue, as shown on histologic specimens; the power used in this study exceeded the power which is used in commercial TCD machines.
Detection of emboli in cardiovascular conditions

Cerebral microemboli can be detected in a variety of cardiovascular conditions and may help in the localization of embolic source. Emboli detection may help in the cardiac sources of emboli with major or minor significance, arterial source of emboli and in monitoring during invasive procedures and surgery.

[1] Localizations of cardiac embolic sources with major significance are as follows:
- Atrial fibrillation
- Valvular (mitral) stenosis
- Myocardial infarction
- Thrombus in left ventricle
- Infective endocarditis
- Myxoma in the left atrium
- Dilated cardiomyopathy

[2] Localizations of cardiac embolic sources with minor significance are as follows:
- Mitral valve prolapse
- Patent foramen ovale
- Aneurysm of atrial septum
- Valvular (aortic, mitral) calcifications
- Prosthetic heart valve

[3] Emboli detection may also help in the localization of arterial sources of emboli, which are as follows:
- Atherosclerotic artery disease
- Carotid stenosis
- Intracranial artery stenosis
- Aortic arch plaques
- Dissection of carotid arteries
- Aortic aneurysm

[4] Cerebral microemboli can be detected by monitoring during invasive procedures and surgery. For example:
- Cardiopulmonary bypass
- Carotid endarterectomy
- Angiography
- Percutaneous transluminal angioplasty

Cardiovascular conditions

Stroke is a relatively frequent complication in patients with cardiovascular diseases; 15–30% of strokes are caused by cardiac diseases. Clinical and epidemiological observations show that patients with thrombi in left ventricle, atrial fibrillation and other cardiac diseases have a higher risk of continuous embolization; these observations have been substantiated by the presence of microembolic signals (MES) in cerebral circulation detected by TCD in patients with such conditions. Prospective studies have shown that recurrent stroke of systemic embolization is high in this group of patients, up to 20%. Strokes due to embolism of cardiac origin are in general severe and prone to early and long-term recurrence. Embolism of cardiac origin can be reliably suspected on clinical grounds but is often difficult to document.

Atrial fibrillation

Atrial fibrillation (AF) is a frequent cardiac rhythm disorder in older patients. AF is present in 1.7% of the population aged 60–64, and in 6% of the population older than 75 years. The incidence of stroke in patients with AF is 4.5% per year. In cases when AF is associated with mitral valve stenosis, the risk of stroke is 17 times higher. The majority of strokes in patients with AF are embolic in origin; emboli signals can be detected in 15–30%. Paroxysmal AF is also considered a risk factor for stroke; the incidence of embolic incidents in patients with paroxysmal AF is similar to that in patients with chronic AF. Ischemic stroke is more severe than in patients with sinus rhythm, the outcome is often fatal; in survivors recurrent stroke is more frequent and neurologic deficit is more severe. Emboli detection in patients with AF can reveal patients at a high risk.

Valvular stenosis

Spontaneous echo contrast can be visualized by transesophageal echocardiography, it appears like a "swirl" or a "cloud" in left atrium and left appendage. This phenomenon is due to erythrocyte aggregation in the presence of macromolecules in conditions of blood stasis. Spontaneous echo contrast is present in patients with AF, dilated atrium and left appendage, prosthetic mitral heart valves and severe ventricular dysfunction. Echo contrast is an independent risk factor for thrombus formation in left atrium and for systemic embolization.

Myocardial infarction

Approximately 2.5% of patients with acute myocardial infarction (MI) will have stroke within 2–4 months. Patients with anterior wall infarct have a stroke risk of 6%, and those with inferior wall (MI) 1%. In a prospective study in patients with anterior wall (MI), emboli signals could be detected in 21%. Mobile thrombi in left ventricle, anterior and apical localization as well as size of dyskinetic wall segment have a predictive value for stroke.
Infective endocarditis

The prevalence of stroke in patients with infective endocarditis is 15—20%. The size of vegetations has a predictive value, the risk of embolization is higher in patients with vegetations larger than 10 mm, and in patients with endocarditis of mitral and mobile vegetations.

Cardiac tumors

Although rare, atrial myxoma is the most frequent primary cardiac tumor, usually present in the left atrium. Due to its fragile nature, myxoma has a high potential for embolization to the brain as well as to other organs.

Dilated cardiomyopathy

Impaired systolic function results in low ejection fraction; when becomes significant, as a frequent complication mural thrombi are being formed. The incidence of embolic complications in patients with cardiomyopathy is 4% per year. Embolic signals are detectable in 1/3 of patients with dilated cardiomyopathy.

Mitral valve prolapse

The prevalence of mitral valve prolapse (MVP) in the general population is 1—15%. Isolated MVP is not considered as a significant risk factor for stroke in older patients, but in younger patients myxomatous change of mitral valves is considered to be in relationship with cerebrovascular incidents.

Patent foramen ovale

The prevalence of patent foramen ovale (PFO) in the general population is 22—34.4%. In patients with so-called cryptogenic stroke due to paradoxical embolism, especially younger patients, a high prevalence of patent foramen ovale (PFO) has been found. The average annual rates of recurrent cerebral ischemia were 3.6%, and for recurrent strokes were 9.9%. TCD has shown to be highly specific and sensitive, and may serve as an excellent alternative method to the gold standard of transesophageal echocardiography (TEE) in the diagnosis of PFO. When performing transesophageal echocardiography (TEE), the presence of patent foramen ovale (PFO) is confirmed if gas bubbles are seen within three cardiac cycles after contrast injection; and while performing TCD microbubbles (MB) are detected in the middle cerebral artery (MCA) 10 s after injection of contrast agent prepared as agitated isotonic saline solution in the cubital vein. Valsalva maneuver performed during contrast injection increases the sensitivity. Patent foramen ovale (PFO) has shown to be a significant risk factor for stroke in younger patients. Two factors have been identified as factors that potentially increase the risk of stroke:

1. Patent foramen ovale (PFO) associated with right-to-left shunt (RLS) — A multicenter study has shown that stroke risk over 4 years is 19.2% in patients with PFO and RLS, and only 5.6% in patients with isolated PFO.
2. Size of patent foramen ovale (PFO) — A study has shown that PFO >2 mm is present in a higher proportion of patients with cryptogenic stroke (26%) than in patients with identified cause (6%). Another study has shown the size of PFO to be >4 mm in patients with stroke as opposed to the healthy control group with the size of PFO <2 mm. As a method for the evaluation of the size of PFO the detection of microbubbles (MB) in the MCA under basal conditions after i.v. contrast or agitated saline injection has been proposed; a four level categorization according to microbubbles’ (MB) count should be applied. A clinical study has shown that the presence of ”curtain” correlates with the highest risk of stroke. The size of right-to-left shunt estimated with TCD may not be in correlation with the size of patent foramen ovale (PFO) estimated with echocardiography, as other factors can influence the blood volume that passes through the shunt. Patent foramen ovale (PFO) is present in a high percentage in scuba divers with complications due to decompression disease; the risk is 2.5—4.5 times higher in patients with PFO. TCD can serve as an excellent screening method for the detection and size of right-to-left shunt; transesophageal echocardiography (TEE) is indicated in shunt positive patients to confirm the localization of the shunt, and to investigate the presence of patent foramen ovale (PFO) or other cardiac abnormalities.
Atherosclerotic disease

Carotid stenosis
Detection of emboli ipsilaterally to carotid stenosis may localize the source of emboli, help in the classification/etiology of cerebrovascular symptoms, and indicate asymptomatic patients with higher stroke risk. The frequency of embolic signals is higher in patients with higher grade of carotid stenosis; stenosis <29% is not prone to embolization, 30–69% stenosis may in certain conditions produce emboli, and stenosis >70% is prone to embolization.63,64 Plaque characteristics are also important: intraluminal thrombosis, irregular plaque surface, and ulceration are in relation with emboli frequency.65,66 Studies have shown great variability of detected emboli in patients with carotid stenosis, however, all studies are consistent in the observation that the frequency of emboli in asymptomatic patients is significantly lower. In one study symptomatic patients with severe carotid stenosis were emboli positive in 77%, and asymptomatic in only 16%.67 In another study emboli were detected in 27% of symptomatic and 2.9% of asymptomatic patients.68 In several studies a shorter time interval between stroke and monitoring was related to the frequency of detected emboli.69,70 Most of the patients with severe carotid stenosis will eventually produce microemboli. However, the production of emboli is random, and it is likely that many hours of monitoring are required to determine whether a patient with symptomatic carotid diseases is emboli positive. Microemboli in these patients can help in the identification of the patients at risk and furthermore indicate periods of transiently increased risk in individual patients.71 After carotid endarterectomy, emboli signals disappear or the frequency is significantly lower.72 Dissection of carotid arteries is an embolic source, and emboli can be detected in a high proportion of these patients.73 TCD was used to monitor cessation of ipsilateral distal microembolization associated with clinical improvement on anticoagulant therapy. The presence of emboli in cerebral circulation can be regarded as a risk factor for stroke.74–76

Aortic arch atheroma
Aortic arch atheroma has long been underestimated as an embolic source. Studies have shown that aortic arch atheroma is a strong and independent risk factor for ischemic stroke. The risk of stroke increases sharply in patients when the thickness of plaques is greater than 4 mm; the attributable stroke risk is 12.6%; microembolic signals can be detected in 14.3% of these patients.77

Monitoring during invasive procedures

Cardiopulmonary bypass
The first of the four decades of cardiac surgical history showed the greatest progress; however, postoperative transient or persistent neurologic deficit is present in a large proportion of patients. Perioperative stroke occurs in 2–3% of adult cardiac surgery patients and significant cognitive dysfunction is experienced by 40–60% of patients in the first postoperative week.78 Perioperative neurocognitive abnormalities are associated with a greatly increased risk of perioperative mortality, lengthy intensive care and hospital stay. Long-term cognitive dysfunction, ranging from months to years, occurs in 25–40% of patients resulting in a decreased quality of life.78 The exact pathophysiological mechanism responsible for postcardiac surgery patients (CABG) deficit is not clear; the two most important are hypoperfusion and microembolism. In patients with postoperative neurologic deficit can be detected twice as high as in patients without emboli signals in cerebral circulation.7 Neurologic deficit was present eight weeks postoperatively in 8.6% of patients in whom <200 emboli during CABG were detected, and in 43% of patients with 1000 detectable emboli per surgery.79 Improvement of technology results in better postoperative outcome: the introduction of filters has resulted in a lower incidence of neurologic lesions (5%) as compared with patients who had the surgery performed with unfiltered machines (27%).79 Observations from these and similar studies indicate that microembolization could be a significant cause of neurologic and cognitive deficits in patients after CABG.

Carotid endarterectomy (CEA)
Prospective studies in patients with high grade carotid stenosis have shown that stroke occurred in patients with cerebral microemboli detected with TCD who had not had a surgery; the risk significantly decreased after CEA and emboli signals had disappeared or significantly decreased.80 Emboli signals can be detected during the exposure and mobilization of the artery, especially during implantation and removal of the shunt and after clamp release.81 The efficacy of CEA largely depends on postoperative results, i.e. perioperative complications. Intraoperative monitoring of hemodynamic changes and detection of microbubbles (MB) may significantly influence postoperative outcome.82 A study in 500 patients has shown that microemboli detected during surgery are the probable cause of cerebrovascular complications in 54%; the incidence of persistent neurologic deficit
decreased from 7% (documented after the first 100 surgeries) to 2% (documented in the next 400 surgeries) when surgeons changed the operative strategy according to intraoperative TCD information.81

**Percutaneous transluminal angioplasty (PTA)**

Advantages and disadvantages of PTA as compared with classic CEA are still a matter of debate. Main disadvantages are attributed to the higher risk of neurologic complications due to hemodynamic ischemia during balloon inflation and microembolization after plaque disruption. Studies have shown inconsistent results. Several studies have shown that despite higher frequency of detected emboli, stroke risk was not higher in patients in whom PTA was performed, whereas others put in doubt the advantages of PTA due to the high frequency of emboli and complications during the procedure.83 The use of cerebral protection devices appears to reduce thromboembolic complications during PTA and stenting; the combined stroke and death rate within 30 days in patients treated with cerebral protection devices was 1.8% as compared with 5.5% in patients without these devices.84 Experimental studies have shown that the majority of microbubbles (MB) are gaseous in origin, whereas microbubbles (MB) detected during balloon inflation are probably attributable to solid particles.85

**Angiography**

Angiography of the aortic arch is associated with 1% risk of stroke with permanent deficit, and 3% risk of mild to moderate stroke or TIA.8,9 In a study with 24 patients undergoing angiography one middle cerebral artery was monitored with TCD for carotid territory ischemia. Microemboli were seen in all patients, with an average of 51 (range 12–154) per procedure, the majority of emboli signals had the characteristics of gas bubbles; the number of detected microbubbles (MB) correlated with the volume of injected contrast, and all patients except one who had stroke were asymptomatic.9 Microbubbles (MB) detected during angiography are attributable to gas bubbles, contrast injection, clot formation in catheter, and disrupted atheromatous material.8,9,86,87

**Discussion**

**Coagulation**

Coagulation mechanisms in patients with stroke, TIA, coronary and other cardiac diseases are not fully understood. Clinical studies have shown that hyperfibrinogenemia is in positive correlation with cardiovascular and cerebrovascular diseases.88,89 Patients with progressive atherosclerosis have higher levels of fibrinogen compared with those with nonprogressive disease.90 Patients with fibrinogen blood level >5 g/L have fourfold risk of thromboembolic complications.91 Embolic signals are detectable with a higher frequency in patients with higher fibrinogen levels.88

**Monitoring of therapeutic efficacy**

Monitoring of therapeutic effect has shown that after CEA emboli disappear or decrease in frequency, a finding consistent across studies.91,92 Studies that investigated the efficacy of anticoagulant and antiaggregation therapy and frequency of emboli have shown various results. Although some studies have shown a decrease in emboli frequency after aspirin or heparin administration, consistent correlation has not been found. However, the CARESS trial (first multicenter, randomized, double blind trial that used microembolic signals’ (MES) detection as endpoint to evaluate antiplatelet therapy) has shown that clopidogrel + aspirin is superior to aspirin alone in reducing the frequency of microembolic signals (MES) in patients with recent symptomatic carotid stenosis. Monitoring of therapeutic efficacy has been consistent after CEA.93–96 S-Nitrosoglutathione (GSNO) is a nitric oxide donor that appears to have relative platelet specificity. The administration of S-nitrosoglutathione (GSNO) in patients with carotid artery stenosis resulted in a rapid reduction in the frequency of embolic signals of 84% at 0–3 h, 95% at 6 h, and 100% at 24 h. Despite its short half-life, S-nitrosoglutathione (GSNO) proved highly effective in rapidly reducing the frequency of embolic signals in this group.96 Glycoprotein IIb/IIIa receptor antagonist tirofiban is a highly selective platelet aggregation inhibitor. The administration of tirofiban resulted in microembolic rate drop from a median range of 38 to zero in patients with severe carotid artery stenosis, however, the inhibitory effect of tirofiban is reversible.97

**Clinical significance of emboli detection**

Clinical significance of emboli detection is not fully elucidated; numerous studies have shown various results. A significantly higher frequency of emboli signals was detected in patients with acute stroke when monitoring was performed within the first couple of hours as compared to
post stroke days. Patients in whom emboli signals are detectable later more frequently have recurrent stroke, often fatal. A certain proportion of patients with detectable emboli signals are asymptomatic, although correlation of cerebral microembolism with clinical symptoms (stroke or TIA ipsilateral to carotid stenosis, higher incidence of stroke in patients with cardiac diseases, neurologic complications after angiography, postoperative neurologic complications after CEA, in patients after CABG) was shown in a number of studies. It is important to emphasize that the vast majority of emboli do not produce immediate symptoms. Great variability of results demonstrated in various studies is attributable to the small number of included patients, inhomogeneous groups, different TCD machines and equipment settings, and different criteria for emboli characterization. Despite disputable clinical significance in certain conditions, the potential benefit of TCD emboli detection is substantial. Emboli in cerebral circulation indicate asymptomatic patients with increased stroke risk. In symptomatic patients the etiology of neurologic deficit may be elucidated and appropriate therapy introduced. Emboli detection may help in differentiation between hemodynamic and embolic stroke. In certain cases emboli detection may indicate the embolic source; in patients with carotid stenosis emboli signals will be detected ipsilaterally to the stenosis, whereas in patients with cardiac diseases emboli can be detected in both middle cerebral arteries (MCAs), or in all cerebral arteries. Patients with cerebral microembolism have higher cognitive deficits; cumulative effect of embolism is thought to be the cause. Even a minor neuropsychological impairment should not be underestimated, and the presence of an embolic source should be regarded as the possible cause of cognitive decline. Imaging techniques (computed tomography, magnetic resonance, diffusion-weighted magnetic resonance image) can show "silent" areas of cerebral ischemia; these small and multiple areas of acute or subacute brain infarction may occasionally present with clinical features atypical for brain embolism or will not produce any apparent symptoms. Besides the size and composition of emboli, other factors play a role in asymptomatic/symptomatic patients; these factors probably include collateral circulation and characteristics of the recipient vessel. Multicenter studies with a large number of patients and standardized monitoring protocols are needed to elucidate the clinical significance of emboli signals in cerebral circulation.

References


58. Schuchlenz HW, Weihs W, Horner S, Quenlenberger F. The association between the diameter of patent foramen ovale


